Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 29002

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Biotechnology
  • Content
  • Gastrointestinal

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29002

License Grant
The collaboration agreement for the provision of Inflammatory Bowel Disease patient samples and IBD clinical  data.

IPSCIO Record ID: 7344

License Grant
The Licensee entered into an exclusive License Agreement (with a right to subLicense) with the Licensor, a nonprofit medical research facility, for the rights to novel modulators of sphingosine phosphate receptors, including modulators to the S1P1R.
License Property
The technology Licensed covers RPC1063.

RMS:  RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).

RPC1063 for the treatment of UC: IBD is comprised of two chronic, autoimmune, GI inflammatory disorders: UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.

Field of Use
RPC1063, is being developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD).

IPSCIO Record ID: 240458

License Grant
The Taiwan Licensee obtained from the Taiwan Licensor the global rights to BEL-DLS01, an API intended to treat inflammatory bowel diseases, and its surrounding proprietary information and platforms to develop, modify, manufacture, distribute and sell pharmaceutical products.
License Property
Investigational drugs that are designed for the treatment of autoimmune diseases, including BLI-1006 to treat inflammatory bowel disease.
Field of Use
With BEL-DLS01 as the API, the Taiwan Licensee is developing BLI-1006 to treat inflammatory bowel disease.

IPSCIO Record ID: 27147

License Grant
The Company exclusive strategic collaboration arrangement in the field of genetic epidemiology with a medical genetics company based in Berlin, Germany.
License Property
A new project agreement provides, among other things, for cooperation on a project in the field of lipid discovery and nuclear receptors.  According to the provisions of the project agreement, the company is to receive DNA samples to enable experiments on target identification and validation.  

The goal of the alliance is to obtain family-based patient data and samples, which are analyzed to identify associations between genes and certain cardiovascular diseases.  The company seeks to generate population data on gene dependent disease susceptibility and drug response behavior in form of a life science database.  The company will own the results of this collaboration, in particular the life science database and has agreed to pay a royalty for the commercial use of this database or the results of this collaboration.

Field of Use
The rights granted are in the field of lipid discovery and nuclear receptors.

IPSCIO Record ID: 210693

License Grant
The Licensor granted the Licensee an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and other IL-23R compounds covered by our patent rights that meet certain requirements for all indications of inflammatory bowel disease,IBD, including CD – Crohns disease and UC – ulcerative colitis.
License Property
The Licensor is a biopharmaceutical company with a proprietary technology platform utilized to discover and develop oral targeted therapy-based peptide drugs including PTG-200 for treatments including the treatment of CD and UC.
Field of Use
The Licensee entered the collaboration agreement for the development, manufacture and commercialization of PTG-200 worldwide.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.